Bloomberg the Company & Products

Bloomberg Anywhere Login


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

Onyx Wins Backing of FDA Advisory Panel for Cancer Drug

Don't Miss Out —
Follow us on:

June 21 (Bloomberg) -- Onyx Pharmaceuticals Inc. gained the most in five years after winning support from a U.S. advisory panel for its drug to treat a deadly blood cancer that affects 50,000 Americans.

Onyx jumped 43 percent to $63.78 at the close in New York, the biggest single-day increase since Feb. 12, 2007. The shares have gained 78 percent in the past 12 months. Ligand Pharmaceuticals Inc., which has an agreement to explore an IV version of the drug, increased 13 percent to $16.49.

Food and Drug Administration advisers voted 11 to 0, with one abstention, that the benefits of Onyx’s multiple myeloma treatment, called carfilzomib, outweigh its risks. If approved by the agency, annual sales may be $523 million in 2016, according to the average of five analysts’ estimates compiled by Bloomberg, more than doubling the South San Francisco-based company’s $447 million revenue last year.

“This is an unmet need in a group that has really run out of options,” said Wyndham Wilson, the panel chairman and chief of lymphoma therapeutics at the National Cancer Institute. “There is a pretty convincing signal here that is likely, I believe, to be confirmed in confirmatory trials.”

The agency, scheduled to make a decision by July 27, isn’t required to follow the recommendation of the panel, which met yesterday in Silver Spring, Maryland. Onyx applied for accelerated approval of the treatment based on the second of three phases of trials typically needed for market clearance.

Tumors Shrunk

The medicine, with the proposed name Kyprolis, shrunk tumors in 22 percent of multiple myeloma patients, which may not offer enough of an advantage in light of the side effects, FDA staff said in a June 18 report.

Five patients died from heart ailments, the agency said. If approved, annual sales for the drug may be $523 million in 2016, according to the average of five analysts’ estimates compiled by Bloomberg, more than doubling Onyx’s $447 million revenue last year.

“This is an incredibly important step in the company’s growth trajectory,” Michael King, an analyst with Rodman & Renshaw in New York, said in an e-mail. “This is a much better drug than the Street has been giving them credit for.”

The panel’s recommendation, “is an important regulatory milestone,” Ted Love, executive vice president of research and development at Onyx, said yesterday in a statement. “Onyx is committed to bringing Kyprolis to patients as quickly as possible and looks forward to working closely with the FDA as the agency completes its review.”

Side Effects

Side effects for the treatment included cardiac arrest, chest pain, pneumonia and shortness of breath, the FDA staff said. More than 70 percent of patients had lung complications with the drug, according to the FDA report.

Carfilzomib would be used to treat multiple myeloma patients who have first tried Celgene Corp.’s Revlimid and Takeda Pharmaceutical Co. Ltd.’s Velcade.

About 50,000 people in the U.S. are living with the disease and 20,000 new cases are diagnosed each year. About 11,000 patients die of the blood cancer annually, according to the National Cancer Institute.

Ligand, a drugmaker based in La Jolla, California, had gained 37 percent in the 12 months before today.

To contact the reporters on this story: Anna Edney in Washington at; Ryan Flinn in San Francisco at

To contact the editor responsible for this story: Reg Gale at

Please upgrade your Browser

Your browser is out-of-date. Please download one of these excellent browsers:

Chrome, Firefox, Safari, Opera or Internet Explorer.